- Home
- CYN vs LGVN Comparison
CYN vs LGVN Comparison
Compare CYN & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYN | LGVN |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8M | 11.9M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CYN | LGVN |
|---|---|---|
| Price | $1.54 | $0.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 1.7M | ★ 8.5M |
| Earning Date | 03-25-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | N/A | ★ N/A |
| Revenue | $368,138.00 | ★ $709,000.00 |
| Revenue This Year | $31.96 | N/A |
| Revenue Next Year | $1,459.25 | $1,183.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.33 | $0.48 |
| 52 Week High | $41.54 | $1.83 |
Technical Indicators
Market Signals| Indicator | CYN | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 39.68 | 56.78 |
| Support Level | $1.33 | $0.60 |
| Resistance Level | $2.85 | $0.99 |
| Average True Range (ATR) | 0.27 | 0.16 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 5.35 | 39.11 |
Price Performance
Historical ComparisonAbout CYN Cyngn Inc.
Cyngn Inc is an industrial autonomous vehicle technology company. Its flagship innovation is DriveMod, an autonomous driving solution that can be flexibly deployed on multiple vehicle types manufactured by Original Equipment Manufacturers in various environments.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.